To include your compound in the COVID-19 Resource Center, submit it here.

Three late-stage wins shift the clinical landscape in SLE

A trio of companies reported positive data from late-stage systemic lupus erythematosis trials, raising hopes that new treatments are on the horizon for an indication that has seen only one new therapy approved in the past 60 years.

At the 2019 American College of Rheumatology (ACR) / Association for Rheumatology Professionals (ARP) annual meeting this week, SLE candidates from AstraZeneca plc (LSE:AZN; NYSE:AZN), Idorsia Ltd. (SIX:IDIA) and RemeGen Ltd., each with different mechanisms, had positive data in Phase II or

Read the full 808 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE